Table 2.
GH use, body composition, and glucose tolerance in TS
| GH (76) | No GH (26) | P | |
|---|---|---|---|
| Age (yr) | 13.9 ± 3.6 | 13.6 ± 3.7 | NS |
| BMI (kg/m2) | 22.2 ± 4.7 | 25.1 ± 7.2 | 0.002a |
| Height sd | -1.93 ± 0.8 | −2.51 ± 1.3 | 0.009a |
| BF (%) | 28.2 ± 8.3 | 35 ± 7.7 | P < 0.0001b |
| SAT (ml)c | 99.5 ± 81.8 | 183.2 ± 37.5 | 0.001b |
| VAT (ml)c | 33 ± 13.7 | 49.8 ± 7.8 | 0.0009b |
| IGT | 7% | 28% | 0.006 |
SAT and VAT were measured by MRI. IGT indicates blood glucose more than 140 mg/dl on oral glucose tolerance test. Data are means ± sd or proportion. Prevalence of IGT was compared by χ 2. GH was not administered the day before or day of metabolic testing. P values remain significant at P < 0.01 after Bonferroni correction. BF, Total body fat measured by DXA.
a
Group means were compared by ANCOVA including age as covariate.
b
Group means were compared by ANCOVA including age and BMI as covariates.
c
Fifty-two GH-treated and 17 untreated girls had MRI abdominal fat measurements.